3 QUESTIONS 1) Why would patients want a needle in the guts 2xweekly for 6 weeks when oral PPS is already on the market (Elmiron), 2) Did PAR's BME project magically become an OA trial, and 3) Buckley's chance of useful patent. All stoppers IMO.
Ann: PAR achieves 100 per cent recruitment in Phase 2b OA Trial, page-11
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.060(13.0%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 56.0¢ | 40.0¢ | $4.475M | 8.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12150 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 39994 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
